Hook & thesis
Exagen is no longer a pure speculative turnaround. The company closed 2025 with record full-year revenue of $66M-$67M, grew AVISE CTD test volume 11%, and expanded trailing 12-month average selling price (ASP) by roughly $30 versus 2024. Cash at year-end rose to $32M, up $10M year-over-year. Taken together, revenue momentum plus a larger cash cushion makes the company’s path to sustained profitability materially more credible.
Short version of the trade: buy into continued execution and margin recovery. Market participants are still wrestling with ASP pressure from the back half of 2025, but Exagen has demonstrable volume growth and unit-price expansion on a trailing basis. At a market cap of about $161M and EV/Sales roughly 2.2x, the reward/risk skew favors a long exposure if you’re willing to hold for operational improvement over the next several quarters.
What Exagen does and why the market should care
Exagen is a commercial-stage diagnostics company focused on autoimmune disease testing under the Avise brand. The business sells specialized laboratory tests designed to improve differential diagnosis and guide therapy for chronic autoimmune conditions. That is a sticky, recurring-revenue type of medical testing business: once clinicians adopt the test, it becomes part of a diagnostic workflow and can sustain contribution margin over time.
Why investors should care: autoimmune diagnostics sits at the intersection of growing incidence, clinical desire to reduce diagnostic odysseys, and the push to use biomarkers to optimize therapy. Exagen’s recent results indicate it is winning share of that demand, with test volume and ASP gains that can drive operating leverage if fixed costs and lab throughput are managed carefully.
Proof points from the numbers
- Revenue: Exagen reported record full-year 2025 revenue of $66M-$67M, up about 19%-20% year-over-year.
- Volume & pricing: AVISE CTD test volumes rose 11% year-over-year, while trailing 12-month ASPs expanded by at least $30 compared with 2024.
- Balance sheet: cash at year-end strengthened to $32M, a $10M improvement versus the prior year, helping fund operations while management drives margin improvement.
- Market valuation: market cap is approximately $161M and enterprise value is about $157M, implying EV/Sales near 2.2x on 2025 revenue.
- Profitability & cash flow: EPS remains negative (latest diluted EPS ~-0.78) and free cash flow was negative ~$7.6M, indicating the company still needs operating improvement to run consistently positive cash flow.
- Technicals & sentiment: recent price momentum is strong (10/20/50-day averages rising; RSI ~74 and MACD showing bullish momentum), but short interest has been notable (recent settled short interest ~978,980 shares as of 07/15/2026), which can amplify intraday moves.
Valuation framing
At a market cap of roughly $161M against $66M-$67M of 2025 revenue, Exagen is trading at about 2.4x market-cap-to-revenue and EV/Sales ~2.2x. For a commercial-stage diagnostics company with clear volume growth and improving ASPs, that multiple is reasonable and leaves room for upside if the company converts top-line momentum into margin expansion.
We should be explicit about where value could show up: incremental margin expansion from higher ASPs and scale, improved payer coverage or higher reimbursement, and a sustained positive free cash flow trajectory would justify multiples above current levels. Conversely, if ASP pressures resume or volume growth stalls, multiple compression could follow.
Catalysts to watch
- Quarterly results: Continued sequential revenue growth and tangible improvement in gross margin or operating leverage would be the clearest near-term catalyst.
- ASP trajectory: If management sustains or accelerates the trailing ASP expansion (the company already shows a ~$30 TTM increase), that should lift revenue per test and margins.
- Payer / coverage wins: Any announcement of broader insurance coverage or favorable reimbursement policies would de-risk demand and shorten the path to profitability.
- Cash-flow inflection: Demonstrating a smaller free cash flow burn or a quarter of positive free cash flow would materially change valuation dynamics for a $161M market cap company.
- Institutional interest / analyst coverage: Upgrades or renewed institutional buying given improved fundamentals could amplify the upside, especially with elevated short interest acting as fuel for squeezes.
Trade plan (actionable)
This is a long trade. The plan below is designed to capture upside from continued operational improvement while respecting the stock’s volatility and technical backdrop.
- Entry: $6.50 (target execution near current market levels; place limit order to avoid chasing spikes).
- Stop loss: $5.25. Put the stop under recent consolidation; a breach would signal momentum failure and a material re-pricing of the story.
- Target: $9.00. This reflects a conservative re-rating to EV/Sales multiple closer to growth-stage diagnostics peers if the company shows margin improvement and sustained revenue acceleration.
- Horizon: long term (180 trading days). Expect the company to need multiple quarters to prove sustainable margin improvement and turn free cash flow positive; give the trade enough runway for fundamental catalysts to play out.
- Risk level: medium. The company has improving fundamentals and a stronger cash position, but still posts negative EPS and negative free cash flow. Position sizing should reflect that risk.
Why this specific entry/exit makes sense
$6.50 is close to current trading levels and sits above short-term moving averages, letting you participate without chasing a steep intraday move. The $5.25 stop is below a reasonable consolidation support band and gives the trade room for normal volatility but cuts losses if operations disappoint. The $9.00 target is achievable without requiring unrealistic multiples: it would imply a market cap near $225M (assuming ~24.96M shares outstanding) and an EV/Sales move toward ~3.3x, which is attainable if the company converts ASP gains and volume growth into clear operating leverage.
Risks and counterarguments
- Pricing pressure could return. Management referenced ASP headwinds in the second half of 2025. If payers or competitors force ASPs down again, the nascent margin recovery could reverse and revenue growth would lose its leverage.
- Profitability is not yet proven. EPS is still negative (~-0.78), and free cash flow was negative about $7.6M. Continued cash burn would necessitate financing or dilution if operating improvements lag expectations.
- Leverage and balance-sheet dynamics. Debt-to-equity sits elevated (about 2.09). While cash improved to $32M, high leverage relative to equity complicates the path to unambiguous profitability and increases sensitivity to revenue shocks.
- Investor sentiment & technical volatility. RSI is elevated (~74) and short interest has been meaningful (nearly 1M settled short shares recently). Those factors can create sharp price swings in both directions.
- Execution risk on payer coverage and adoption. The product’s long-term thesis relies on broader adoption and payer support; delays in coverage updates or slower clinician uptake would push out the timeline to profitability.
Counterargument: The most compelling counterargument is that 2025’s ASP improvement could prove transitory if pricing competition intensifies or payers push back, leaving Exagen as a revenue-growing but unprofitable lab requiring additional capital. That scenario would materially compress valuation and could produce downside beyond the proposed stop.
What would change my mind
I would downgrade the thesis if any of the following occur: a) a quarter with sequential revenue decline or negative year-over-year volume, b) a return to widening negative free cash flow without a credible plan to fix it, or c) material adverse payer decisions that roll back reimbursement or limit coverage for key tests.
Conversely, I would become more bullish if Exagen reports consecutive quarters of positive operating leverage, posts a quarter of positive free cash flow, or announces meaningful payer wins that lock in higher ASPs or substantially broaden access.
Bottom line
Exagen has moved from speculative to tactical: record revenue ($66M-$67M), unit growth (+11% AVISE CTD volume), ASP expansion (TTM +$30), and a stronger cash position ($32M) create a credible pathway to profitability. The valuation - roughly $161M market cap and EV/Sales ~2.2x - leaves upside if management converts top-line momentum into margin gains. The trade here is a long with a clear entry at $6.50, a protective stop at $5.25, and a target of $9.00 over a 180-trading-day horizon. Balance the position size to reflect ongoing negative EPS and cash-flow risk, and watch quarterly results and ASP trends as the primary read-throughs on the thesis.